3 Growth Companies On The Indian Exchange With Insider Ownership Up To 25%
Reviewed by Simply Wall St
Over the last 7 days, the Indian market has dropped 4.0%, driven by declines in every sector. In contrast to this recent dip, the market is up 40% over the past year and earnings are forecast to grow by 17% annually. In such a fluctuating environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business.
Top 10 Growth Companies With High Insider Ownership In India
Name | Insider Ownership | Earnings Growth |
Archean Chemical Industries (NSEI:ACI) | 22.9% | 36% |
Kirloskar Pneumatic (BSE:505283) | 30.6% | 30.1% |
Dixon Technologies (India) (NSEI:DIXON) | 24.6% | 35.5% |
Jupiter Wagons (NSEI:JWL) | 10.8% | 27.2% |
Shivalik Bimetal Controls (BSE:513097) | 19.5% | 28.7% |
Happiest Minds Technologies (NSEI:HAPPSTMNDS) | 31.9% | 20.7% |
Paisalo Digital (BSE:532900) | 16.3% | 23.8% |
JNK India (NSEI:JNKINDIA) | 20.9% | 31.8% |
Rajratan Global Wire (BSE:517522) | 19.8% | 35.8% |
KEI Industries (BSE:517569) | 19.1% | 20.3% |
Let's take a closer look at a couple of our picks from the screened companies.
One97 Communications (NSEI:PAYTM)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: One97 Communications Limited operates in India, offering payment, commerce and cloud, and financial services to consumers and merchants with a market cap of ₹317.76 billion.
Operations: Revenue segments for One97 Communications Limited include Data Processing, which generated ₹91.38 billion.
Insider Ownership: 20.7%
One97 Communications, known for its high insider ownership, has faced recent challenges including a significant regulatory penalty and widening net losses in Q1 2024. Despite these setbacks, the company continues to expand strategically through partnerships like the one with FlixBus and new product launches such as 'Paytm Health Saathi.' While earnings are forecasted to grow substantially per year, revenue growth is expected to outpace the Indian market but remain below 20% annually.
- Dive into the specifics of One97 Communications here with our thorough growth forecast report.
- The analysis detailed in our One97 Communications valuation report hints at an deflated share price compared to its estimated value.
Senco Gold (NSEI:SENCO)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Senco Gold Limited manufactures and trades in jewelry and articles made of gold, silver, platinum, and other precious and semi-precious stones in India with a market cap of ₹76.50 billion.
Operations: The company's revenue primarily comes from the sale of gold jewelry and other articles, amounting to ₹52.41 billion.
Insider Ownership: 24.1%
Senco Gold, characterized by high insider ownership, has shown robust financial performance with annual earnings forecasted to grow significantly at 21.4%. Recent board changes and regulatory challenges have not impacted its operations. The company reported strong revenue growth for FY2024, reaching ₹52.84 billion from ₹41.09 billion the previous year. Although trading below analyst price targets and offering good relative value compared to peers, its Return on Equity is projected to be low at 17.4%.
- Delve into the full analysis future growth report here for a deeper understanding of Senco Gold.
- Our valuation report unveils the possibility Senco Gold's shares may be trading at a discount.
Solara Active Pharma Sciences (NSEI:SOLARA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Solara Active Pharma Sciences Limited operates in India by manufacturing, producing, processing, formulating, selling, importing, merchandising, distributing, trading in and dealing with active pharmaceutical ingredients (API), with a market cap of ₹31.46 billion.
Operations: Revenue from active pharmaceutical ingredients (API) amounts to ₹13.00 billion.
Insider Ownership: 25.9%
Solara Active Pharma Sciences, with significant insider ownership, is forecasted to achieve above-average market growth, becoming profitable within three years. Despite a volatile share price and recent dilution from a ₹4.50 billion equity offering, the company reaffirmed its revenue guidance of up to ₹15 billion for FY2025. Recent earnings showed modest sales growth but continued net losses. Regulatory compliance at its Visakhapatnam facility strengthens its operational credibility in the pharmaceutical sector.
- Take a closer look at Solara Active Pharma Sciences' potential here in our earnings growth report.
- The valuation report we've compiled suggests that Solara Active Pharma Sciences' current price could be quite moderate.
Seize The Opportunity
- Investigate our full lineup of 89 Fast Growing Indian Companies With High Insider Ownership right here.
- Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
- Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Looking For Alternative Opportunities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NSEI:SOLARA
Solara Active Pharma Sciences
Manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.
Undervalued with reasonable growth potential.
Similar Companies
Market Insights
Community Narratives


